Posts by: Isaura Santos

Isaura Santos

Isaura Santos graduated with a BS in Cell and Molecular Biology from Universidade Nova de Lisboa and a MA in Communication, Culture and Information Technologies from University Institute of Lisbon (ISCTE-IUL). Her professional interests include science communication, public awareness of science and communication of science through entertainment.

March 20, 2015March 20, 2015

Teen With IBD Conquers 13.1 Mile Marathon For Crohn’s Disease And Ulcerative Colitis

News, Ulcerative colitis

Chayla is a beautiful 16 year old girl. Although she is missing her hair and might look like she is going through cancer chemotherapy, she is not. She is one of ... Read more

March 6, 2015March 6, 2015

The Giving Tree Is Walking For Inflammatory Bowel Diseases

News

The Giving Tree Wellness Center, a medical dispensary of marijuana in Phoenix, Arizona announced that they will be participating in the Take Steps for Crohn’s and Colitis Foundation at the Phoenix Zoo. Crohn’s ... Read more

March 2, 2015March 2, 2015

Ferring Pharma Announces EU Launch Of CORTIMENT®MMX® (budesonide) For Ulcerative Colitis

News, Ulcerative colitis

Ferring Pharmaceuticals recently announced the European launch of CORTIMENT® MMX® (budesonide) to address active mild and moderate ulcerative colitis (UC) — the first and only approved oral drug for the disease. The company has ... Read more

February 26, 2015September 28, 2016

Hospira Presents Updates on Biosimilar Inflectra for IBD at 2015 ECCO-IBD Conference

News

Recently, IBD News Today reported on how Hospira, Inc. announced the launch of Inflectra (infliximab), the first biosimilar monoclonal antibody (mAb), in major European markets. Now, the company has been invited ... Read more

February 24, 2015February 24, 2015

Hospira Launches First Biosimilar Monoclonal Antibody for Adult & Pediatric Crohn’s, Ulcerative Colitis In Europe

News, Ulcerative colitis

Hospira, Inc., a biotechnology company developing biosimilar therapies, has recently announced the launch of Inflectra (infliximab), the first biosimilar monoclonal antibody (mAb), in major European markets. Inflectra is licensed to address several inflammatory conditions such as rheumatoid arthritis, ... Read more

February 17, 2015February 17, 2015

TiGenix And Lonza Partner For Complex Perianal Fistulas In Crohn’s Disease Treatment

Crohn's Disease, News

TiGenix, an advanced biotechnological company committed to developing and marketing new therapeutics from allogeneic expanded adipose-derived stem cells (eASCs) for autoimmune and inflammatory diseases, together with Lonza, a leading and global company of ... Read more

February 16, 2015February 16, 2015

VG Life Sciences Secures Patent For Cell-Protective IBD Treatment

IBD News, News

VG Life Sciences (VGLS), a biotechnology company committed to developing therapies for infectious and autoimmune diseases, recently announced that the U.S. Patent and Trademark Office (USPTO) has issued the company a Patent No. 8906846 covering a ... Read more

February 11, 2015February 12, 2015

Second Genome’s New IBD Drug Advances To Phase 1 Trial

IBD News, News

Second Genome Inc. recently advanced SGM-1019, the company’s primary microbiome drug indicated for inflammatory bowel disease (IBD), to Phase 1 clinical testing to identify an optimal dose. Peter DiLaura, President and the CEO of the company, said ... Read more

February 4, 2015February 5, 2015

Crohn’s & Colitis Foundation of America Announces that President & CEO Richard J. Geswell Is Retiring

News

After almost 10 years leading the Crohn’s & Colitis Foundation of America (CCFA), Richard J. Geswell, the CEO and President of the Foundation, will be retiring at the end of the ... Read more

February 3, 2015February 3, 2015

New JustLikeMeIBD.org Website For Kids And Teens With Inflammatory Bowel Diseases

IBD News, News

In response to the steadily growing number of children and teenagers suffering with inflammatory bowel disease (IBD) in the United States — which has now reached an estimated 1.6 million people, 10 percent of whom ... Read more